Your TMS schedule is full, referrals are coming in, and prior authorization approvals are piling up in an inbox. Then a denial arrives. Quick answer: Read the denial notice immediately, record its reason and every deadline, alert the ordering provider, and request a peer-to-peer review if the payer offers one. Start the written appeal process at the same time. A denial does not guarantee that treatment cannot be authorized, but deadlines and payer-specific requirements matter.
What should you do first when TMS insurance coverage is denied?
First, identify exactly what the payer denied and what action it allows next. A TMS prior authorization denied for missing documentation calls for a different response than one denied because the plan says a coverage criterion was not met.
Picture a busy TMS clinic with an approved treatment plan and a steady flow of referrals. The denial notice lands in a shared inbox, but no one is assigned to open it. Sessions continue to be scheduled while the team assumes someone else is handling the payer response. Days pass, and the peer-to-peer window or appeal deadline gets closer.
The risk is not just the first denial. It is letting a response deadline pass, or discovering that the approval covers fewer sessions or a shorter period than the clinical plan requires. If the payer authorized only an initial block, do not assume that a planned 36-session course is covered in full.
The turning point is recognizing that a denial may be addressed through the payer’s review process, but only if someone owns the next step. The American Medical Association’s 2024 prior authorization survey reported an average of 39 prior authorization requests per physician per week. With that volume, a clear owner and deadline log matter.
Why are TMS and Spravato prior authorizations denied?
Denials can stem from missing records, mismatched criteria, benefit-routing errors, or an authorization that no longer matches the planned care. Common documentation gaps include:
- Medication trials listed without exact dates, doses, duration, response, or reason for stopping. The payer may require evidence of specific prior trials, but criteria vary by plan.
- Missing baseline or follow-up symptom measures, such as PHQ-9 or MADRS scores, when the plan asks for them.
- Medical-necessity language that does not clearly address the payer’s stated criteria.
- The request sent to the wrong plan administrator or behavioral health carve-out, such as Optum, Carelon, or Magellan.
- For Spravato, missing information about REMS certification or the required administration and observation process.
- A TMS approval that has ended or reached its session limit before the treatment course is complete.
For Spravato, the official prescribing information describes required monitoring after administration. Check the current label and REMS requirements, along with the patient’s plan rules. For a step-by-step front-end checklist, see Almonord’s Spravato prior authorization guide.
What should your team do in the first 48 hours?
Treat the first two days as an internal response target, not a universal payer deadline. A faster response gives the practice more time to clarify the denial and meet whatever deadline the notice sets.
- Read the full denial notice. Record the reason, date, next review option, required submission method, and filing deadline.
- Clarify the issue. Determine whether the denial is administrative, such as missing information or incorrect routing, or clinical, such as a stated medical-necessity concern.
- Notify the ordering provider. Share the denial reason and any peer-to-peer options as soon as possible.
- Gather the relevant record. Pull the medication trial history, symptom measures, treatment plan, and any other documents that address the reason given.
- Request a peer-to-peer if offered. Ask who must participate, how to schedule it, and whether a written appeal is also required.
- Assign an owner and log the dates. Do not rely on an inbox flag or someone’s memory.
A request for peer-to-peer should not be assumed to extend or replace the formal appeal deadline. Confirm the process with the payer and follow the instructions in the notice.
How does a peer-to-peer review work?
A peer-to-peer review is a conversation between the treating clinician and a payer’s clinical reviewer, when the payer makes that option available. Industry guidance describes these calls as often scheduled quickly, sometimes within 24 to 72 hours, but that is not a universal deadline or guarantee. Check the denial notice and contact the payer promptly. A TMS appeals overview discusses this commonly reported scheduling pattern.
The treating psychiatrist should be ready to explain the clinical reasoning, not just repeat what is already in the file. Prepare concise answers about the diagnosis, treatment history, documented response or intolerance, current symptom measures, requested service, and how the case relates to the payer’s criteria. Keep the relevant records available during the call.
A missed peer-to-peer opportunity can remove one route for timely clinical discussion. It does not necessarily mean every formal appeal option is gone, so check the denial notice rather than assuming. Record the reviewer’s name, the call date, what was discussed, and the decision or next steps.
What documentation can support a TMS denial appeal?
Build the appeal around the denial reason. A complete packet may include:
- The denial notice and the specific payer policy or criteria cited.
- A dated medication history that lists each relevant drug, dose, duration, outcome, and reason for discontinuation.
- Baseline and ongoing PHQ-9, MADRS, or other measures requested by the plan.
- The treating provider’s explanation of medical necessity, organized to address the stated criteria.
- For Spravato, relevant REMS certification and the practice’s plan for the required administration and observation steps.
- For TMS, the treatment plan and the session count requested, checked against the authorization already granted.
The goal is not to send a larger packet for its own sake. It is to make the missing information or clinical rationale easy for the reviewer to find. For the initial TMS submission and common documentation requirements, see Almonord’s TMS authorization guide.
Which deadlines apply to 2026 prior authorization decisions?
CMS-0057-F sets decision timeframes for certain impacted payers. Beginning January 1, 2026, applicable impacted payers must decide standard prior authorization requests within seven calendar days and expedited requests within 72 hours. The rule also requires specific reasons for certain denials. Check the CMS fact sheet for the scope and details.
These timeframes are not a universal appeal-filing deadline. CMS-0057-F applies to specified payer categories, and its prior authorization process provisions exclude drugs. A Spravato drug authorization therefore follows the payer’s applicable drug pathway, not automatically the rule’s service decision timeframe. Do not assume the rule applies to every commercial plan or every TMS or Spravato review.
Appeal filing and decision timelines depend on the plan, payer, and applicable rules. The denial notice should state how to appeal and by when. Confirm the requirement with the payer and your plan documents. For background on the rule’s scope, see Almonord’s CMS-0057-F guide.
What should go in a denial and appeal log?
Keep one secure, consistently used record for each denial. Include:
- Patient identifier, payer, plan, and carve-out
- Service requested and denial reason
- Denial date and appeal deadline
- Peer-to-peer date, assigned owner, and outcome
- Written appeal submission date and confirmation
- Current status, next follow-up date, and final outcome
Every deadline needs a named owner and a backup. Use your practice’s approved system and privacy safeguards. This guide to authorization tracking covers keeping approvals and reauthorization tasks visible as treatment progresses.
How can you prevent the next denial or authorization lapse?
The useful reframe is that a denial is not always a payer dead end. Sometimes the missing piece is an incomplete record, an unclear next step, or no one assigned to the clock.
At intake, capture medication-trial details and the symptom measures required by the relevant plan. Verify which payer or carve-out handles the request before submitting it. For an active course, compare the treatment schedule with the approved dates and session count, and start reauthorization before the final approved session. Use the same ownership and deadline discipline for denials as for routine authorizations.
People searching how to appeal a denied TMS claim may be dealing with a different process. This guide covers a prior authorization denial before or during planned treatment, not a post-service claim dispute.
Frequently asked questions
Should we request a peer-to-peer or file a written appeal first?
Request a peer-to-peer promptly if the payer offers one, and separately follow the written appeal instructions and deadline in the denial notice.
Does requesting a peer-to-peer pause the appeal deadline?
Do not assume it does, so confirm the deadline and process directly with the payer.
Does CMS-0057-F apply to every TMS or Spravato request?
No, it applies to specified payer categories and excludes drug prior authorization processes.
What should the clinician prepare for a peer-to-peer review?
The clinician should be ready to explain the relevant treatment history, clinical rationale, requested service, and how the case addresses the payer’s stated criteria.
What is the most important information to track after a denial?
Record the denial reason, every deadline, the assigned owner, the next action, and confirmation that the payer received the response.
This article is for informational purposes only. It is not legal, medical, or compliance advice. Requirements vary by payer, plan, and state. Confirm applicable requirements with the payer, your contracts, and qualified counsel.
Almonord AI Solutions provides front-end patient-access support for behavioral health practices, including prior authorization and reauthorization tracking, insurance verification, denial prevention, credentialing, and front-desk workflows. We do not provide back-end billing or marketing. If you want an experienced review of where front-end processes may be creating avoidable risk, request a free Revenue Leak Audit.
Prevention First. Not Damage Control.